Summary
The contamination of autologous marrow with clonogenic tumor cells has been the main argument against ABMT in acute leukemia.
In a preclinical study we evaluated an active cyclophosphamide derivative named “ASTA Z 7557”. We observed that the toxic effect of this drug on CFU-GM growth was dependent on nucleated cell concentration as well as on red blood cell contamination. The potency of the drug was in close relationship with the incubation temperature.
The growth of leukemic CFU was inhibited with an ASTA Z dose higher than 30 μg/ml. In our system, beyond 40 μg/ml more than 95% of committed stem cells are destroyed.
Fifteen patients had autotransplant because of AML for 10 patients and because of ALL for 5 patients (4 patients were grafted in relapse and 11 patients in remission).
We demonstrated that the marrow take was possible although the inoculum is CFU-GM depleted.
Five of the 10 AML patients are alive and remain disease-free at 45 +, 65 +, 190 +, 345+ and 570 + days from ABMT without any maintenance treatment. Four of the 5 ALL patients are alive, three of them in complete remission (404+, 110+, 250+ days).
The number of patients reported in this clinical study was relatively small and more cases should be evaluated to be conclusive. Nevertheless the feasibility of chemopurified ABMT was demonstrated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dicke KA, Spitzer G, Peters L: Autologous bone marrow transplantation in relapsed adult acute leukemia. Lancet 3: 514–517, 1979
Herve P, Rozenbaum A, Plouvier E, Flesch M, Cahn JY, Farradji A, Berjerat JP, Adjizian JC, Pignon B: Autologous bone marrow transplantation in acute myeloid leukemia in relapse or in complete remission. Cancer Treat Rep 66:1983–1985, 1982
Herzig GP: Autologous marrow transplantation in cancer therapy. Prog Hematol 12:1–23, 1981
Vellekoop L, Dicke KA, Zander AR: Repeated high dose cyclophosphamide, BCNU and VP-16-213 and autologous bone marrow transplantation in adult acute lymphocytic leukemia in 1st remission. Eur J Cancer Clin Oncol, (submitted)
Sarpel SC, Epstein RB: Chemoseparation of cell populations in dogs by activated cyclophosphamide. Blood 54:230, 1979
Takamizawa A, Matsumoto S, Iwata T, Katagiri K, Tochino Y, Yamaguchi K: Studies on cyclophosphamide metabolites and their related compounds. Preparation of an active species of cyclophosphamide and some related compounds. J Amer Chem Soc 95:985–986, 1973
Iscove NN, Senn JS, Till JE, McCulloch EA: Colony formation by normal and leukemic human marrow cells in culture. Effect of conditioned medium from human leukocytes. Blood 37:5–12, 1971
Dao C, Zittoun R, Cadiou M, Bilski-Pasquin G, Bousser J: La culture de moelle osseuse chez l'homme. Numération des cellules donnant des colonies de granuleux et de macrophages. Pathol Biol (Paris), 23:717–727, 1975
Herve P, Coffe C, Peters A: Méthode de concentration des cellules-souches médullaires utilisant le laveur IBM 2991. Rev Fr de Transfusion et Immuno-Hématol 26:207–216, 1983
Herve P, Tamayo E, Coffe C, Lenys R, Peters A: Cryopreservation of human bone marrow with a view to autologous bone marrow transplantation. In JL Touraine (ed): Bone Marrow Transplantation in Europe, Excerpta. Medica, Amsterdam, 1979, pp 80–87
Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galon DAG, Gralnick HR, Sultan C: Proposals for the classification of acute leukemia. Brit J Haematol 33:451–458, 1976
Colvin M, Hilton J: Pharmacology of cyclophosphamide and metabolites. Cancer Treat Rep 65:89–95, 1981
Sharkis SJ, Santos GW, Colvin M: Elimination of acute myelogenous leukemic cells from marrow and tumor suspensions in the rat with 4-hydroperoxycyclophosphamide. Blood 55:521–523, 1980
Kaizer H, Stuart RK, Colvin M, Körbling M, Wharam MD, Santos GW: Autologous bone marrow transplantation in acute leukemia: a pilot study utilizing in vitro incubation of autologous marrow with 4-Hydroperoxycyclophosphamide (4-HC) prior to cryopreservation (abstract). Exp Hematol 9 (suppl. 9): 190, 1981
Körbling M, Hess AD, Tutschka PJ, Kaizer H, Colvin M, Santos GW: 4-Hydroperoxycyclophosphamide: a model for eliminating residual human tumour cells and T-lymphocytes from the bone marrow graft. Brit J Haematol 52:89–96, 1982
Herve P, Tamayo E, Peters A: Autologous stem cell grafting in acute myeloid leukaemia: technical approach of marrow incubation in vitro with pharmacological agents (prerequisite for clinical applications). Brit J Haematol 53:683–684, 1983
Gartner S, Kaplan H: Long-term culture of human bone marrow cells. Proc Natl Acad Sci USA 77:4756–4759, 1980
Maraninchi D, Abecasis M, Gastaut JA, Sebahoun G, Cahn JY, Herve P, Novakovitch G, Carcassone Y: High-dose Melphalan and autologous bone marrow transplant for relapsed acute leukaemia. Cancer Chemother Pharmacol 10:109–111, 1983
Dicke KA, Vellekoop L, Spitzer G, Zander AR, Schell F, Verma DS: Autologous bone marrow transplantation in neoplasia. In RP Gale and CF Fox (eds): Biology of Bone marrow Transplantation, Academic Press, New York, 1980, pp 159–165
Izzi T, Moretti L, Polchi P, Galimberti M, Delfini C, Porcellini A, Lucarelli G: Autologous bone marrow transplant in complete remission acute leukemia. Exp Hematol 11 (suppl. 13):150–151, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hervé, P., Cahn, J.Y., Plouvier, E. et al. Autologous bone marrow transplantation for acute leukemia using transplant chemopurified with metabolite of oxazaphosphorines (ASTA Z 7557, INN mafosfamide). Invest New Drugs 2, 245–252 (1984). https://doi.org/10.1007/BF00232359
Issue Date:
DOI: https://doi.org/10.1007/BF00232359